Innovent Biologics, Inc. · HKEX:1801

Innovent Biologics — 43rd Annual J.P. Morgan Healthcare Conference (January 2025)

30 slides from Innovent Biologics's conference presentation, Jan 16, 2025

  1. Slide 1: 43rd Annual J.P. Morgan Healthcare Conference

    43rd Annual J.P. Morgan Healthcare Conference Michael Yu, Ph.D., Founder, Chairman and CEO 16 January 2025 TO EMPOWER PATIENTS WORLDWIDE WITH AFFORDABLE, HIGH-QUALITY BIOPHARMACEUTICALS

  2. Slide 2: Agenda

    Agenda 1 Innovent Strategy for Second Decade 2 Oncology: “IO + ADC” 3 General Biomedicine: New Growth Pillar 4 2025 Outlook 2

  3. Slide 3: Agenda

    Agenda 1 Innovent Strategy for Second Decade 2 Oncology: “IO + ADC” 3 General Biomedicine: New Growth Pillar 4 2025 Outlook 3

  4. Slide 4: Innovent's strategy in second decade of operation: positioned for sustainable growth

    Innovent’s strategy in second decade of operation: positioned for sustainable growth and aimed at global innovation Global innovation Be a global biopharma company 20 launched products Achieve RMB20bn annual sales 13 Commercial products New high-potential drugs 2030+ 24 140KL Incl. GCG/GLP-1, IGF-1R

  5. Slide 5: Comprehensive world-class technology platforms as innovation powerhouse

    Comprehensive world-class technology platforms as innovation powerhouse ScFv Topo1i Dual-payloads Antibody-peptide T cell engager VHH bispecific NovaKine® InnoBody® engineering ADC ADC conjugate Innovent Academy Confidential Copyright© 2025 Innovent 5

  6. Slide 6: Oncology and general biomedicine: key growth pillars

    Oncology and general biomedicine: key growth pillars comprising a diversified pipeline of new-generation therapies Oncology CVM Autoimmune Ophthalmology “PD-1 + precision therapy” Extensive and significant Global BIC/FIC pipeline to Commitment to elevate leadership strengthened growth opportunities

  7. Slide 7: Agenda

    Agenda 1 Innovent Strategy for Second Decade 2 Oncology: “IO + ADC” 3 General Biomedicine: New Growth Pillar 4 2025 Outlook Confidential Copyright© 2025 Innovent 7

  8. Slide 8: Leverage "IO + ADC" strategy to transform cancer treatment

    Leverage “IO + ADC” strategy to transform cancer treatment Oncology leadership strengthened Next wave of global innovation gaining momentum PD-1 backbone Precision therapies New generation IO New generation ADC • Tyvyt® as a leading brand of PD-(L)1 • One of the most comprehensive • Differentiated l

  9. Slide 9: World-class antibody engineering + versatile ADC platforms

    World-class antibody engineering + versatile ADC platforms to produce balanced and differentiated ADC candidates • Deep understanding of disease biology World-class antibody engineering platform • NGS-based antibody discovery technology and proprietary multi-specific platforms • Stochastic and site-

  10. Slide 10: 8 ADCs in clinical trials and more at IND-enabling stage

    8 ADCs in clinical trials and more at IND-enabling stage IBI343 (CLDN18.2 ADC) IBI130 (TROP2 ADC) IBI133 (HER3 ADC) IBI3009 (DLL3 ADC) Dual payload ADC Bispecific ADC Phase 3 Phase 1/2 Phase 1 Phase 1 Phase 1 in 2025 IND-enabling stage More preclinical programs IBI354 (HER2 ADC) IBI129 (B7H3 ADC) IB

  11. Slide 11: IBI354 (HER2 ADC): novel TOPO1i HER2 ADC to enter Ph3

    IBI354 (HER2 ADC): novel TOPO1i HER2 ADC to enter Ph3 with validated robust efficacy and superior safety High response and superior safety in HER2+ gyn. cancers cORR & DCR ≥Grade 3 TRAEs ILD incidence IBI354 clinical PK supports superior safety profile HER2 1/2/3+ OC (mainly 1+) HER2 2/3+ OC HER2+ s

  12. Slide 12: IBI3009 (DLL3 ADC): potentially best-in-class DLL3 ADC against SCLC

    IBI3009 (DLL3 ADC): potentially best-in-class DLL3 ADC against a key antigen target of SCLC Foundational and competitive target for SCLC ─ High prevalence and high internalization rate (80-90% in SCLC) ─ Expression restricted to tumor cells and is validated via DLL3 TCEs and other ADC clinical data

  13. Slide 13: IBI3009 (DLL3 ADC): global exclusive license agreement with Roche

    IBI3009 (DLL3 ADC): entered global exclusive license agreement with Roche to advance the treatment in SCLC ADC platform technology with In-depth scientific expertise and differentiated innovation global development capabilities Global rights US$80mn Collaboration US$1bn to exclusively develop, manuf

  14. Slide 14: IBI343 (CLDN18.2 ADC): encouraging efficacy in both GC and PDAC

    IBI343 (CLDN18.2 ADC): novel site-specific TOPO1i CLDN18.2 ADC shows encouraging efficacy in both GC and PDAC GC: PoC achieved with superior safety; Ph3 ongoing; BTD granted Phase 1b Publications at ESMO GI 2024 ≥G3 nausea ≥G3 vomitting 22.0% IBI343 (CLDN18.2 ADC) 15.0% • 6mg/kg (n=30*), ORR=36.7%，D

  15. Slide 15: IBI363 (PD-1/IL-2α-bias): first-in-class immuno-cytokine

    IBI363 (PD-1/IL-2α-bias): first-in-class immuno-cytokine based on redefining findings, shows initial efficacy and safety signals in a variety of cancers First-in-class α-biased IL-2 and anti-PD-1 immuno-cytokine ▪ Efficacy：IL-2Rα-bias selectively activates PD-1+CD25+ TST cells and synergizes with PD

  16. Slide 16: IBI363: ongoing Phase 1b/2 studies as next-generation IO therapy

    IBI363 (PD-1/IL-2α-bias): ongoing Phase 1b/2 studies to evaluate the potential as a next-generation IO therapy Overcome Turn Feasible for Replace IO SoC IO resistance cold tumors to combination (e.g. PD-L1<1%) tumors hot tumors therapy ▪ The results of Phase 1 study supported our preclinical finding

  17. Slide 17: Agenda

    Agenda 1 Innovent Strategy for Second Decade 2 Oncology: “IO + ADC” 3 General Biomedicine: New Growth Pillar 4 2025 Outlook Confidential Copyright© 2025 Innovent 17

  18. Slide 18: Well positioned for significant commercial opportunities with fast-growing portfolio

    Well positioned for significant commercial opportunities with competitive, fast- growing portfolio 1 Broad addressable patient base 2 BIC/FIC product profiles 3 Lifecycle management 500mn Obesity/ SINTBILO® First domestic PCSK9 drug Adults affected * overweight Key indications to secure 200mn Hyperl

  19. Slide 19: Mazdutide (GCG/GLP-1): robust weight loss and cardiometabolic benefits

    Mazdutide (GCG/GLP-1): achieves robust weight loss, special liver benefits and improvements on cardiometabolic risk factors for obese and overweight population 1 Robust Weight Loss -18.6% -21.0% 6mg 48W weight reduction1 16mg 20W weight reduction2 Mazdutide activates both GCGR and GLP-1R 2 Special L

  20. Slide 20: Mazdutide: lifecycle management and next-gen innovation

    Mazdutide (GCG/GLP-1): lifecycle management and next-gen innovation to serve significant unmet needs that overlap with and go beyond obesity Moderate-to- severe obesity Oral delivery Obesity NME in IND-enabling GLORY-2 (9mg) Higher dose in plan 25H2 readout & NDA T2D with obesity Novel modalities &

  21. Slide 21: Teprotumumab (IGF-1R): potential first IGF-1R drug for thyroid eye disease in China

    Teprotumumab (IGF-1R): potential first IGF-1R drug for thyroid eye disease in China RESOTRE-1 Ph3 endpoint met in support of first NDA under review Proptosis responder rate in the study eye1 after 24w treatment 85.8% Teprotumumab Placebo 1m-4m 70.4% Prevalence of TED 48.1% Difference 100+k 81.9% 27.

  22. Slide 22: Picankibart (IL-23p19): best-in-class profiles for psoriasis

    Picankibart (IL-23p19): best-in-class profiles demonstrated by robust data for psoriasis treatment CLEAR-1 Ph3 in support of first NDA in review; biologics-switching Ph2 validated BIC profiles Picankibart (IL-23p19) YTE mutation Q12W 80.3% 64.6% Globally first IL23p19 achieved PASI 90 >80% at Subjec

  23. Slide 23: Agenda

    Agenda 1 Innovent Strategy for Second Decade 2 Oncology: “IO + ADC” 3 General Biomedicine: New Growth Pillar 4 2025 Outlook Confidential Copyright© 2025 Innovent 23

  24. Slide 24: Strong growth trajectory targeting RMB20bn product sales in 2027

    Strong growth trajectory targeting RMB20bn product sales in 2027 and beyond to drive global expansion RMB 20bn IBI363 (PD-1/IL-2α-bias) IBI3002 (IL-4Rα/TSLP) IBI343 (CLDN18.2 ADC) IBI355 (CD40L) IBI3003 (GPRC5D/BCMA/CD3) IBI356 (OX40L) IBI3001 (EGFR/B7H3 ADC) IBI3016 (AGT siRNA) VEGF/C XOI IBI3009 (

  25. Slide 25: Continued robust revenue growth and improved financial performance in 2024

    Continued robust revenue growth and improved financial performance in 2024 Over 50% yoy leap in product revenue for 2024Q1-Q3 Significantly narrowed EBITDA loss Healthy financial position RMBm RMBm ~6.2bn -73.0% -39.9% Over US$1.4bn Cash and Cash Equivalent 50+% 2022 2023 2023H1 2024H1 4.1bn (161) (

  26. Slide 26: Positioned for a fruitful 2025 to unlock significant growth opportunities

    Positioned for a fruitful 2025 to unlock significant growth opportunities 6 new products launch in 2025 Rapid growth momentum anticipated Launch time (est. ) 2025 Jan DOVBLERON® (ROS1 TKI) Sustained leading position in oncology; TYVYT® and other key products continue to gain momentum JAYPIRCA® 2025

  27. Slide 27: Key product development milestones are anticipated in 2025

    Key product development milestones are anticipated in 2025 Oncology General Biomedicines NDA & registra- IBI310 TYVYT® IBI343 Fulzerasib Mazdutide Mazdutide IBI302 (CTLA-4)+TYVYT® (PD-1) (CLDN18.2 ADC) (KRAS G12C) (GCG/GLP-1) (GCG/GLP-1) (VEGF/C) tional studies 3L GC 1L NSCLC Obesity (9mg) T2D w.obe

  28. Slide 28: Summary and key takeaways

    Summary and key takeaways 1 2 3 Strong prospects for high- Lifecycle management to Driving global innovation potential launches and growth maximize portfolio value through solid R&D platforms We continued building on our oncology leadership We invest in improving magnitude and longevity of We deploy

  29. Slide 29: Disclaimer

    Disclaimer This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of Innovent Biologics (“Innovent” “we,” “us” or “our”), our bu

  30. Slide 30: Confidential

    Confidential Copyright© 2025 Innovent 30

Innovent Biologics — 43rd Annual J.P. Morgan Healthcare Conference (January 2025) on 6ix